Results 111 to 120 of about 13,106 (183)

Efficacy of azacitidine and trametinib against leptomeningeal melanosis associated with congenital melanocytic nevus syndrome. [PDF]

Mol Cell Pediatr
Raljević L, Komlosi K, Feige U, Eckenweiler M, Lassmann S, Jrad HBH, Werner M, Fischer J, Has C, Feuchtinger T, Uhl M, Niemeyer CM, Hettmer S.   +12 more
europepmc   +1 more source

Budget Impact of Venetoclax for Newly Diagnosed Patients with Acute Myeloid Leukemia Aged ≥ 75 Years or with Comorbidities Precluding Intensive Chemotherapy in the United States. [PDF]

Adv Ther
Xu Y, Nguyen J, Miu K, Lin CW, Montez M, Chai X, Chen X, LeBlanc TW.   +7 more
europepmc   +1 more source

The prognostic value of maintaining minimal residual disease status in patients with acute myeloid leukaemia receiving azacitidine-based therapy. [PDF]

BMC Cancer
Wang JF, Cheng J.
europepmc   +1 more source

Survival of myelodysplastic syndrome patients after azacitidine therapy. [PDF]

BMC Cancer
Thammagul K, Limpiwakee S, Chantrathammachart P, Puavilai T, Chuncharunee S, Niparuck P.   +5 more
europepmc   +1 more source

On the RAdR in relapsed T-cell lymphoma. [PDF]

Blood Adv
Casan JML, Van Der Weyden C.
europepmc   +1 more source

Efficacy and Safety of Azacitidine Combined With Lisaftoclax in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome With Increased Blasts. [PDF]

EJHaem
Meng S, Zhao W, Zhang H, Lei B, Zhang W, Zhang Y, Wang J, Chen Y, Cao X, Gu L.   +9 more
europepmc   +1 more source

Case Report: Iliac perivascular myeloid sarcoma presenting with iliofemoral deep vein thrombosis and hydronephrosis. [PDF]

Front Oncol
Shan Z, Wang Y, Wang H, He J, Cai H.
europepmc   +1 more source

Pharmacological boosting of azacitidine/venetoclax in acute myeloid leukemia. [PDF]

Blood Neoplasia
Westra N, Cerro ER, Schilder E, Lub-de Hooge MN, Touw DJ, Kosterink JGW, Chitu DA, Ammatuna E, Klein SK, Westerweel PE, Cuijpers M, Cruijsen M, Corsten MMF, Alhan C, Tick L, Schuringa JJ, Huls G, Woolthuis CM, Oude Munnink TH.   +18 more
europepmc   +1 more source

Clinical advancement in the management of mutant isocitrate dehydrogenase (<i>IDH</i>) cancers. [PDF]

EJC Suppl
Bridgewater J, Tabatabai G, Macarulla T, Stacchiotti S.   +3 more
europepmc   +1 more source

Venetoclax as a trigger for autoimmune hemolytic anemia in secondary acute myeloid leukemia: A case report. [PDF]

SAGE Open Med Case Rep
Benallaoua K, Lacoeuilhe P, Gendrot B, Muhammad S, Fouquet G.   +4 more
europepmc   +1 more source